title: Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
abstract: Following the discovery of the Janus kinase (JAK) 2 V617F mutation in 2005 the explosion of research and drug development activity has not only advanced our understanding of the pathogenesis of myeloproliferative neoplasms (MPNs) but also triggered debate about classification, allowed revised diagnostic and response criteria, provided a target for treatment and a mode of monitoring its success. These changes and the resultant clinical research are discussed in this article where we argue that discovery of the JAK2 V617F mutation has signalled the much delayed change in therapeutic paradigm for myelofibrosis and possibly other MPNs from palliation and allowing us to move closer to, but not yet attain, a cure.
authors.affiliation: Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK. claire.harrison@gstt.nhs.uk
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.forename: Mary F
authors.initials: MF
authors.lastname: McMullin
authors.forename: Ruben
authors.initials: R
authors.lastname: Mesa
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000201:enzymology; D010166:Palliative Care; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D053614:Janus Kinase 2; D053612:Janus Kinases